About Nuclear transcription factor Y subunit gamma
Nuclear transcription factor Y subunit gamma (NFYC) is a protein
from Homo sapiens identified by UniProt accession
Q13952, 458 residues long.
MolForge cross-references it against 0 known binders and
58 disease associations.
Target properties
| Protein name | Nuclear transcription factor Y subunit gamma |
| UniProt accession | Q13952 |
| Gene | NFYC |
| Organism | Homo sapiens |
| Length | 458 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (58)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.54
- body height · score 0.18
- neoplasm · score 0.05
- Chronic Obstructive Asthma · score 0.05
- cancer · score 0.04
- cyst · score 0.04
- lung adenocarcinoma · score 0.03
- lymphocyte count · score 0.03
- small cell lung carcinoma · score 0.02
- non-small cell lung carcinoma · score 0.02
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q13952-F1 | alphafold | PREDICTED | 49.47 | — |
Amino-acid sequence (458 residues)
MSTEGGFGGT SSSDAQQSLQ SFWPRVMEEI RNLTVKDFRV QELPLARIKK IMKLDEDVKM ISAEAPVLFA KAAQIFITEL TLRAWIHTED NKRRTLQRND IAMAITKFDQ FDFLIDIVPR DELKPPKRQE EVRQSVTPAE PVQYYFTLAQ QPTAVQVQGQ QQGQQTTSST TTIQPGQIII AQPQQGQTTP VTMQVGEGQQ VQIVQAQPQG QAQQAQSGTG QTMQVMQQII TNTGEIQQIP VQLNAGQLQY IRLAQPVSGT QVVQGQIQTL ATNAQQGQRN ASQGKPRRCL KETLQITQTE VQQGQQQFSQ FTDGQRNSVQ QARVSELTGE AEPREVKATG NSTPCTSSLP TTHPPSHRAG ASCVCCSQPQ QSSTSPPPSD ALQWVVVEVS GTPNQLETHR ELHAPLPGMT SLSPLHPSQQ LYQIQQVTMP AGQDLAQPMF IQSANQPSDG QAPQVTGD
Explore Nuclear transcription factor Y subunit gamma with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets